Opinion|Videos|October 1, 2024

Multi-Modal Treatment Strategy for HFmrEF and HFpEF

Javed Butler, MD, MPH, MBA, discusses the additional benefits of combining finerenone with sodium-glucose cotransporter-2 inhibitors for treating heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF as well as how a multimodal approach used in HF with reduced EF can be adapted for managing these conditions.

Video content above is prompted by the following:

  1. What additional benefits does adding finerenone offer when combined with sodium-glucose cotransporter-2 inhibitors for the treatment of heart failure with midrange ejection fraction (HFmrEF) and HF with preserved EF (HFpEF)?
  2. When considering the multimodal approach for the treatment of HF with reduced EF, how can that strategy now be implemented for the management of HFmrEF and HFpEF?
  3. What results were presented?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo